| Retifanlimab studied in …STUDIED_INderived65 of 65show fewer |
|---|
| → studied in | NCT06149481Phase 1/Phase 2 · recruiting Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) · 65 trials list this drug (30 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04472429Phase 3 · completed Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). · 65 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05287113Phase 2 · completed Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck · 65 trials list this drug (30 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06610682early Phase 1 · recruiting A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma · 65 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04387084Phase 1 · active not recruiting Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy · 65 trials list this drug (30 active) | — | — | Malignant Skin Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04438824Phase 2 · active not recruiting Palbociclib and INCMGA00012 in People With Advanced Liposarcoma · 65 trials list this drug (30 active) | — | — | Liposarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04577014Phase 1/Phase 2 · recruiting Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma · 65 trials list this drug (30 active) | — | — | Sarcoma,Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04470024Phase 1 · active not recruiting Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC · 65 trials list this drug (30 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04374305Phase 2 · recruiting Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) · 65 trials list this drug (30 active) | — | — | Meningioma,Vestibular Schwannoma,Ependymoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06072612Phase 3 · recruiting Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. · 65 trials list this drug (30 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06873789Phase 1/Phase 2 · terminated A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors · 65 trials list this drug (30 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06389799Phase 2 · recruiting A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) · 65 trials list this drug (30 active) | — | — | Dedifferentiated Liposarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07772245Phase 2 · not yet recruiting Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer · 65 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04370704Phase 1/Phase 2 · completed Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies · 65 trials list this drug (30 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07425054Phase 2 · recruiting ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer · 65 trials list this drug (30 active) | — | — | Anal Squamous Cell Carcinoma,Human Papillomavirus-Related Carcinoma,Malignant Anal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07765836Phase 2 · not yet recruiting Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC · 65 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06056895Phase 2 · active not recruiting Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma · 65 trials list this drug (30 active) | — | — | Merkel Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06959537Phase 1 · recruiting A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC) · 65 trials list this drug (30 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06179160Phase 1 · recruiting A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation · 65 trials list this drug (30 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06320405Phase 1/Phase 2 · recruiting Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors · 65 trials list this drug (30 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04205812Phase 3 · completed Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer · 65 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07677579Phase 2 · not yet recruiting NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer · 65 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07468136Phase 1/Phase 2 · recruiting Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas · 65 trials list this drug (30 active) | — | — | Anaplastic Oligodendroglioma,Astrocytoma, IDH-Mutant, Grade 4,Astrocytoma, IDH-Mutant, Grade 3+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04225039Phase 2 · active not recruiting Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma · 65 trials list this drug (30 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05455697Phase 1/Phase 2 · active not recruiting Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma · 65 trials list this drug (30 active) | — | — | Diffuse Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04463771Phase 2 · completed Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. · 65 trials list this drug (30 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04494009Phase 2 · active not recruiting PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy · 65 trials list this drug (30 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05743595Phase 1 · active not recruiting Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma · 65 trials list this drug (30 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04968106Phase 2 · active not recruiting Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO) · 65 trials list this drug (30 active) | — | — | Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03328026Phase 1/Phase 2 · completed Combination Study of SV-BR-1-GM With Retifanlimab · 65 trials list this drug (30 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05345002Phase 2 · recruiting All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma · 65 trials list this drug (30 active) | — | — | Glioma,Astrocytoma,Oligodendroglioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06939036Phase 1/Phase 2 · terminated Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) · 65 trials list this drug (30 active) | — | — | Merkel Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05594290Phase 2 · active not recruiting Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery · 65 trials list this drug (30 active) | — | — | Merkel Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07219576Phase 1/Phase 2 · recruiting Retifanlimab and Ruxolitinib In Solid Malignancies · 65 trials list this drug (30 active) | — | — | Lung Non-Small Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05083754Phase 1 · recruiting Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma · 65 trials list this drug (30 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06910137available An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC) · 65 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03532295Phase 2 · completed Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas · 65 trials list this drug (30 active) | — | — | Glioblastoma,Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04586244Phase 2 · terminated An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma · 65 trials list this drug (30 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03522142Phase 1 · terminated A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies · 65 trials list this drug (30 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04989387Phase 1 · terminated Study of INCA 0186 in Subjects With Advanced Solid Tumors · 65 trials list this drug (30 active) | — | — | Solid Neoplasm,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03597295Phase 2 · completed A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) · 65 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02475213Phase 1 · completed Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer · 65 trials list this drug (30 active) | — | — | Malignant Head and Neck Neoplasm,Melanoma,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03599713Phase 2 · completed A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) · 65 trials list this drug (30 active) | — | — | Merkel Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03059823Phase 1 · completed A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors · 65 trials list this drug (30 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04116073Phase 2 · completed INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer · 65 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04580485Phase 1 · completed INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors · 65 trials list this drug (30 active) | — | — | Head and Neck Squamous Cell Carcinoma,Hepatocellular Carcinoma,Lung Non-Small Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04082364Phase 2/Phase 3 · completed Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer · 65 trials list this drug (30 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm,HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05440942Phase 1 · completed Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma · 65 trials list this drug (30 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04231981Phase 2 · completed Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS) · 65 trials list this drug (30 active) | — | — | Malignant Penile Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04445844Phase 2 · active not recruiting INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study · 65 trials list this drug (30 active) | — | — | Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06160206Phase 2 · recruiting Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma · 65 trials list this drug (30 active) | — | — | Glioblastoma,WHO Grade 4 Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04949191Phase 2 · terminated The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. · 65 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05177133Phase 2 · recruiting Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) · 65 trials list this drug (30 active) | — | — | Esophageal Adenocarcinoma,Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04634825Phase 2 · terminated Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer · 65 trials list this drug (30 active) | — | — | Head and Neck Neoplasm,Malignant Head and Neck Neoplasm,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05359692Phase 2 · withdrawn INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma · 65 trials list this drug (30 active) | — | — | Squamous Cell Carcinoma,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03679767Phase 2 · completed A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) · 65 trials list this drug (30 active) | — | — | Melanoma,Lung Non-Small Cell Carcinoma,Clear Cell Renal Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04799431Phase 1 · withdrawn Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer · 65 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03589651Phase 1 · completed INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors · 65 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02393248Phase 1/Phase 2 · terminated Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) · 65 trials list this drug (30 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03406949Phase 1 · completed MGD009/MGA012 Combination in Relapsed/Refractory Cancer · 65 trials list this drug (30 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03910530Phase 1 · completed A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors · 65 trials list this drug (30 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04129320Phase 2/Phase 3 · withdrawn Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck · 65 trials list this drug (30 active) | — | — | Malignant Head and Neck Neoplasm,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04776876Phase 2 · withdrawn Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome · 65 trials list this drug (30 active) | — | — | Neuroendocrine Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04203511Phase 3 · withdrawn INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) · 65 trials list this drug (30 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03920839Phase 1 · withdrawn INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) · 65 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |